What is the State of Vaccination in the UK in 2026?
Vaccination is one of the most cost-effective public health interventions in the history of medicine, and the United Kingdom has a long tradition of high national immunisation coverage that has historically protected millions of people from diseases once responsible for widespread childhood death and disability. But in 2026, that tradition is under measurable strain. While the UK’s vaccination infrastructure — delivered through the NHS and monitored by the UK Health Security Agency (UKHSA) — remains among the most sophisticated in the world, coverage rates for several critical vaccines have been declining for years, and the consequences are now visible in disease surveillance data in ways that public health officials describe with increasing urgency. The 2024-25 annual Childhood Vaccination Statistics, now published by UKHSA, show that MMR (measles, mumps and rubella) coverage at five years of age has fallen to 83.7% in England — down from 88.2% just ten years ago, and nearly 12 percentage points below the 95% threshold that the World Health Organisation (WHO) considers necessary for herd immunity against measles. The result was the worst measles outbreak in England in a generation: nearly 3,000 confirmed cases in 2024 — the highest number for decades.
The UK vaccine statistics in 2026 tell a story of structural unevenness that cuts across programme types, age groups, geographies, and socioeconomic strata. Flu vaccine uptake in the over-65s held at 70% in the 2025-26 campaign, broadly consistent with prior years, but uptake among clinical risk groups under 65 and pregnant women remains stubbornly well below the WHO’s 75% target. COVID-19 autumn 2025 booster coverage reached 62% of those aged 75 and over — respectable but below the peak pandemic-era figures. Meanwhile, the Spring 2026 COVID campaign has been launched targeting the most vulnerable, with monthly data published as of June 4, 2026. The core challenge across virtually every UK vaccination programme in 2026 is not vaccine supply or availability — it is a widening gap in uptake between more and less affluent communities, between London and the rest of England, and between the most engaged and most disengaged population groups. That gap, if not closed, will continue to translate directly into preventable illness, preventable hospitalisation, and preventable death.
Interesting Facts About UK Vaccination in 2026
UK VACCINE STATISTICS FAST FACTS — 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
MMR2 coverage (5-yr-olds, 2024-25): 83.7% England ████████████████████
WHO target for herd immunity (MMR): 95% ████████████████████
Measles cases 2024: ~3,000 (highest for decades) ████████████████████
Measles cases 2025: 959 confirmed (by Nov 2025) ████████████████████
Hackney MMR2 coverage (5-yr-olds): 58.3% — 1 in 2 unprotected
Flu vaccine 65+: 74.9% (2024-25 season) ████████████████████
Flu vaccine pregnant women: 35.0% (2024-25) ████████████████████
Flu vaccine clinical risk <65: 40.0% (2024-25) ████████████████████
COVID autumn booster (75+): 62% (by end Nov 2025) ████████████████████
COVID spring 2026: monthly data published June 2026 ████████████████████
18.2M+ people vaccinated for flu in 2024-25 season ████████████████████
Flu vaccination averted 96,000–120,000 hospital admissions (2024-25)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Interesting Fact | Detail / Data |
|---|---|
| MMR2 coverage at age 5 (England, 2024-25): 83.7% | Down from 88.2% ten years ago — the lowest in at least a decade |
| MMR2 coverage excluding London: 86.6% | London’s exceptionally low MMR rates significantly drag down the England average |
| WHO herd immunity target for measles: 95% | No area in England achieves ≥95% MMR2 coverage for five-year-olds in 2024-25 |
| Measles cases in 2024: ~3,000 | Nearly 3,000 confirmed cases — highest number in England and Wales for decades |
| Measles cases by November 2025: 847 confirmed | Lower than 2024’s peak but still vastly above pre-decline baseline |
| Child died from measles in Liverpool (2025) | A child in Liverpool died from measles in 2025 — first UK measles death in years |
| Hackney MMR2 coverage (5-yr): 58.3% | Just over 1 in 2 five-year-olds in Hackney protected — among the lowest in England |
| Enfield: 34 lab-confirmed measles cases Jan–Feb 2026 | Active measles outbreak; over 60 suspected cases reported by 7 schools and a nursery |
| Flu vaccine 65+: 74.9% (2024-25) | Approaching but below the WHO 75% target; down from 77.8% in 2023-24 |
| 18.2 million+ flu vaccinations given (2024-25) | Most current full-season figure — over 18.2 million GP-registered patients vaccinated |
| Flu programme averted 96,000–120,000 hospital admissions | UKHSA modelling estimate for the 2024-25 influenza vaccination programme |
| COVID autumn booster (75+, by Nov 2025): 62% | Of all people aged 75+ in England; 67% of older adult care home residents |
Source: UKHSA annual COVER report 2024-25 (published August 2025); UKHSA Seasonal Influenza Vaccine Uptake in GP Patients 2024-25 (GOV.UK, published May 22, 2025); Community Practitioner “Is childhood vaccine uptake in freefall?” (March 26, 2026); NHS England Statistics — Flu and COVID Vaccinations page; NHS England Winter Response page; Nuffield Trust “Vaccination coverage for children and mothers” (current); AOL/The Independent “Mapped: Areas with lowest MMR rates” (2026); Sanofi Flunomics England Scorecard 2025
The figures in this table represent a quiet but serious public health regression. The 83.7% MMR2 coverage at five years of age in England in 2024-25 is not merely a statistical shortfall below a WHO target — it is a real-world immunity gap that directly caused the near-3,000 measles cases recorded in 2024 and the ongoing outbreak activity visible in North-East London in early 2026. Professor Mary Ramsay, former director of immunisation at UKHSA, described measles as the “canary in the coalmine” — the most infectious disease on Earth, the first to resurface when vaccination coverage slips, and therefore the clearest early warning that the broader immunisation programme needs urgent intervention. When Hackney has an MMR2 coverage rate of 58.3% — meaning roughly 4 in 10 five-year-olds are unprotected — the question is not whether measles will circulate in that community, but how severely.
The flu programme’s avoidance of 96,000 to 120,000 hospital admissions in 2024-25 — UKHSA’s own modelling estimate — is the most powerful economic argument for sustained investment in vaccine uptake. NHS hospital capacity is among the most politically visible and resource-constrained dimensions of UK public life, and preventing six-figure quantities of hospital admissions through vaccination represents both a direct clinical benefit and a major system-wide efficiency gain. Yet the 74.9% flu coverage in the over-65s in 2024-25 — itself just below the WHO 75% target and declining from 77.8% — confirms that even in the highest-priority and most-engaged age group, uptake is moving in the wrong direction. For pregnant women at 35% and clinical risk groups under 65 at 40%, the gap between where coverage is and where it needs to be for meaningful population protection is substantial and persistent.
UK Childhood Vaccination Coverage in 2026 | MMR, 6-in-1 & Key Rates
UK CHILDHOOD VACCINATION COVERAGE — 2024-25 (UKHSA)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
COVERAGE AT 12 MONTHS (England):
6-in-1 (DTaP/IPV/Hib/HepB) dose 1: 94.0% ████████████████████
PCV (pneumococcal) dose 1: 93.5% ████████████████████
MenB dose 1: 93.7% ████████████████████
COVERAGE AT 24 MONTHS (UK overall):
DTaP/IPV/Hib/HepB + PCV booster + MMR1: >85% all UK nations
MMR1 at 2 years: ~92% ████████████████████
MMR1 at 5 years: 92.3% ████████████████████
6-in-1 at 5 years: 93.2% ████████████████████
COVERAGE AT 5 YEARS (England):
MMR2: 83.7% ████████████████████
MMR2 excluding London: 86.6% ████████████████████
dTaP/IPV (4-in-1) booster: 82.4% ████████████████████
WHO target for all vaccines: 95% ████████████████████ (missed)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Vaccine / Age Milestone | 2024-25 Coverage | Trend |
|---|---|---|
| 6-in-1 (DTaP/IPV/Hib/HepB) dose 1 at 12 months | Approximately 94.0% (England) | Stable; slight improvement |
| 6-in-1 coverage at 5 years | 93.2% — increased 0.1 percentage points | Small improvement year-on-year |
| dTaP/IPV (4-in-1) pre-school booster at 5 years | 82.4% — decreased 1.2 percentage points | Declining |
| MMR1 at 5 years | 92.3% — remained stable | Flat |
| MMR2 (second dose) at 5 years — England | 83.7% | Down from 84.0% in 2023-24; down from 88.2% ten years ago |
| MMR2 at 5 years excluding London | 86.6% | Significantly higher than England average — London drives the national decline |
| DTaP/IPV/Hib/HepB + PCV + MMR1 at 2 years (UK nations) | Over 85% for all four UK countries | England and Northern Ireland lower than Scotland and Wales |
| Scotland and Wales MMR2 at 5 years | Higher than England — both nations outperform England on MMR2 | Consistent across multiple years |
| Hackney MMR2 (5-year-olds) | 58.3% — lowest among reported London boroughs | Critical — below 60% means majority unprotected |
| Enfield MMR2 (5-year-olds) | 64.3% — one of the lowest nationally | Active measles outbreak by January–February 2026 |
| Haringey MMR2 (5-year-olds) | 65.0% | Adjacent to areas with active outbreaks |
| WHO herd immunity threshold (measles) | 95% for both doses | No area in England achieves this for 5-year MMR2 |
Source: UKHSA annual COVER report 2024-25 (August 2025); Community Practitioner “Is childhood vaccine uptake in freefall?” (March 26, 2026); Nuffield Trust “Vaccination coverage for children and mothers” (current 2024-25 data); UKHSA COVER dashboard (ukhsa-dashboard.data.gov.uk); AOL/The Independent “Mapped: Areas of England with the lowest MMR vaccine rates” (2026)
MMR2 uptake rates across the UK are failing to reach pre-pandemic levels or the WHO targets, and the childhood vaccination data for 2024-25 confirms that the post-pandemic recovery in coverage has been partial at best. The recovery in early childhood vaccines — with the 6-in-1 dose at 12 months sitting at approximately 94% and broadly stable — suggests that parents are broadly engaging with the infant vaccination schedule at a reasonable rate. The problem intensifies as children get older. By age five, the MMR second dose coverage falls to 83.7% — nearly 11 percentage points below what the 6-in-1 vaccine achieves at the same age. This gap reflects the challenge of the pre-school booster visit: unlike the infant schedule, which is driven by GP invitations at set infant ages, the pre-school booster requires a separate appointment that families must actively attend, and many — particularly in London, lower socioeconomic areas, and communities with lower institutional trust — do not return.
The London MMR crisis is the most geographically concentrated public health emergency in the UK’s childhood immunisation programme in 2026. With all London boroughs below 80% MMR2 coverage for five-year-olds, and multiple boroughs below 65%, the capital has effectively lost herd immunity for measles across large swathes of its population. The January–February 2026 Enfield outbreak — 34 laboratory-confirmed cases, 60+ suspected cases across seven schools and a nursery — is a direct consequence. The National Immunisation Programme Health Equity Audit 2025, published by UKHSA in March 2026, found that the gap between the most and least deprived IMD deciles for flu uptake in the 65+ group was 11.6 percentage points, and higher for other vaccines — confirming that the coverage crisis is not random but follows the well-worn channels of UK socioeconomic inequality.
UK Flu Vaccine Uptake in 2026 | Seasonal Campaign Data & Key Groups
UK FLU VACCINE UPTAKE BY COHORT — 2024-25 AND 2025-26 SEASONS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Cohort 2024-25 2023-24 WHO target
─────────────────────────────────────────────────────────────
65+ years (GP) 74.9% 77.8% 75%
Clinical risk <65 (GP) 40.0% 41.4% —
Pregnant women (GP) 35.0% 32.1% —
2-3 year olds (GP) 42.6% 44.4% —
Care home residents 71% — —
(by Nov 2025, 2025-26)
65+ (by Nov 2025, 70% — 75%
2025-26 early figure)
Flu vaccine effectiveness: 70-75% (children 2-17)
30-40% (adults)
Total vaccinated 2024-25: 18.2 million+
Hospital admissions averted: 96,000–120,000
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Flu Vaccine Cohort | 2024-25 Final Uptake | 2023-24 Uptake | Change |
|---|---|---|---|
| Aged 65 years and over (GP-registered) | 74.9% | 77.8% | -2.9 pp |
| Aged 6 months to under 65 in clinical risk groups | 40.0% | 41.4% | -1.4 pp |
| Pregnant women | 35.0% | 32.1% | +2.9 pp (achieved national ambition) |
| 2 and 3 year olds (combined) | 42.6% | 44.4% | -1.8 pp |
| 2 year olds | 41.7% | 44.1% | -2.4 pp |
| 3 year olds | 43.5% | 44.6% | -1.1 pp |
| 65+ in 2025-26 season (by late November 2025) | ~70% (interim figure) | — | Campaign still ongoing when published |
| Care home residents (2025-26, by late Nov 2025) | 71% | — | — |
| Pregnant women (2025-26, by late Nov 2025) | 42% (interim) | — | Up from 35% final figure in 2024-25 |
| Total GP-registered patients vaccinated (2024-25) | Over 18.2 million | Over 18.8 million | Slight decrease |
| Flu vaccine effectiveness 2025-26 (children 2-17) | 70-75% at preventing hospital attendance | — | Strong paediatric protection |
| Flu vaccine effectiveness 2025-26 (adults) | 30-40% | — | Lower adult effectiveness typical |
Source: UKHSA Seasonal Influenza Vaccine Uptake in GP Patients in England: Winter Season 2024-25 (GOV.UK, published May 22, 2025, corrected May 28, 2025); NHS England Winter Response page (current, 2025-26 interim figures); Sanofi Flunomics England Country Scorecard 2025 (citing UKHSA 2024-25 modelling estimates)
The 2024-25 flu vaccine uptake data tells a story of a programme that is holding but not improving — and in some critical cohorts, slipping. The 74.9% uptake in the over-65s is the group’s lowest recorded rate in several years, falling below the WHO’s 75% target for the first time since the pandemic period, and declining from 79.9% in 2022-23 — a three-year downward drift that public health officials view with concern given that older adults account for the vast majority of flu-related hospitalisations and deaths. The clinical risk group rate of 40% is a persistent failure: these are adults under 65 for whom flu carries elevated risks of serious illness — people with diabetes, heart disease, respiratory conditions, and immunocompromising conditions — yet fewer than 2 in 5 are vaccinated. The pregnant women rate of 35% represents an improvement on the prior year and met the government’s national uptake ambition, but it still means nearly two-thirds of pregnant women are unprotected from a virus that carries elevated risk of severe illness and preterm birth.
The 2025-26 interim figures — released via the NHS England Winter Response page before the final April 2026 publication — suggest a slightly more mixed but broadly comparable picture. Pregnant women’s early-season figure of 42% outpaced the prior year’s final rate, which may reflect improvements in primary care promotion and antenatal appointment integration. The flu vaccine’s 70-75% effectiveness in children but only 30-40% in adults in 2025-26 reflects a well-documented pattern of age-dependent vaccine response that is partly biological and partly linked to the strain-matching accuracy of the seasonal formulation. The estimate that the 2024-25 programme averted between 96,000 and 120,000 hospital admissions in England is UKHSA’s most direct quantification of the programme’s system-wide value — and it makes the case for closing the uptake gaps not merely as a matter of individual protection, but as one of the most cost-efficient investments available to the NHS.
UK COVID-19 Vaccine Uptake in 2026 | Autumn 2025 & Spring 2026 Campaign Data
UK COVID-19 VACCINATION — AUTUMN 2025 & SPRING 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
AUTUMN 2025 CAMPAIGN (from Oct 1, 2025):
Aged 75+: 62% (by end Nov 2025)
Care home residents 75+: 67% (by end Nov 2025)
Immunocompromised 6m+: 38% (by end Nov 2025)
Frontline NHS workers: data published by NHS England
Co-administered COVID+flu: data tracked weekly/monthly
COVID campaign ended: January 31, 2026
Autumn/Winter data final: published February 5, 2026
SPRING 2026 CAMPAIGN:
Campaign launched: Spring 2026
Data publication: Monthly — first published June 4, 2026
Most vulnerable groups targeted (Spring programme ongoing)
HISTORICAL CONTEXT:
COVID vaccination programme start: December 8, 2020
Total UK COVID vaccinations administered: 100s of millions
Autumn 2023 care home uptake (by June 30, 2024): 68%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| COVID Vaccine Metric | Data |
|---|---|
| Autumn 2025 COVID vaccine: aged 75+ (by end Nov 2025) | 62% of all people aged 75+ in England |
| Autumn 2025: older adult care home residents (by end Nov 2025) | 67% of older adult care home residents |
| Autumn 2025: immunocompromised aged 6 months+ (by end Nov 2025) | 38% of those with weakened immune systems resident in England |
| Autumn 2025 COVID campaign end date | Campaign formally ended January 31, 2026 |
| Final Autumn/Winter 2025-26 COVID data published | Monthly data covering November 6, 2025 to February 5, 2026 released |
| Spring 2026 COVID vaccination campaign | Launched in Spring 2026 targeting most vulnerable groups; monthly data publication began June 4, 2026 |
| Autumn 2024 care home COVID uptake (by June 30, 2024) | 68% of all older adult care home residents |
| COVID co-administration with flu (2025-26) | Co-administration of COVID and flu vaccines tracked monthly from November 2025 onwards |
| Frontline NHS healthcare workers (autumn 2025) | Flu and COVID uptake tracked fortnightly up to October 2025, then weekly from November |
| COVID programme historical start | UK COVID vaccination programme began December 8, 2020 — the first country in the world to administer approved COVID vaccines |
Source: NHS England Statistics — COVID-19 Vaccinations page (england.nhs.uk/statistics, current); NHS England Winter Response page (current, with figures as of late November 2025); NHS England Statistics supplementary analysis July 2024 (care homes spring campaign); NHS England Statistics — Flu Vaccinations page (final 2025-26 campaign publication April 16, 2026)
The UK’s COVID-19 vaccination programme in 2026 has transitioned from the mass-population emergency mobilisation of the pandemic years into a risk-stratified seasonal programme targeting defined vulnerable groups — primarily the over-75s, care home residents, and immunocompromised individuals. The 62% autumn booster coverage in the over-75s by end of November 2025 reflects a programme that is reaching the majority of its highest-priority cohort, though there is meaningful room to improve: the 67% care home resident figure confirms that the most vulnerable institutional population is being well-served, while the 38% immunocompromised uptake suggests that a substantial proportion of people with weakened immune systems — for whom COVID remains a serious and potentially life-threatening illness — are not receiving the recommended protection.
The transition to monthly data publication in March 2026 — with the Spring 2026 campaign’s first monthly statistics released on June 4, 2026 — reflects the normalisation of COVID vaccination as a routine seasonal programme rather than an emergency response. The Spring 2026 campaign targets those who were not covered adequately in autumn and those for whom seasonal top-up protection is clinically indicated, continuing the NHS’s commitment to keeping the most vulnerable protected in a landscape where COVID-19 remains endemic but has receded as a mass emergency. The UK’s distinction of being the first country in the world to administer approved COVID vaccines — on December 8, 2020, when 90-year-old Margaret Keenan received the Pfizer-BioNTech jab — remains a point of historical pride, and the ongoing programme demonstrates that the infrastructure and population familiarity with routine vaccination built during the pandemic years is now being applied to a broader seasonal risk management framework.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
